In its decision published on WednesdayExternal link, the St Gallen court said that “fake” marijuana – i.e. cannabis containing less than 1% tetrahydrocannabinol (THC) – was sold primarily to be smoked, and therefore should be taxed similarly to tobacco.
It thus upheld the decision taken by the Federal Customs Administration in February 2017, which stipulated that such cannabis products be bundled together with fine grain tobacco – taxed at CHF38 ($37.70) per kilo as well as 25% of retail revenue.
The decision had been challenged by a distributor of legal cannabis, who the court said was advertising the flowers on its website in combination with smoking paraphernalia, among other items.
The decision thus rejects the complainant’s appeal but is not final; it can yet be brought before the supreme court, Switzerland’s highest court.
The decision affects only marijuana flowers, i.e. the part of the plant to be smoked, not other legal cannabis-related products.
Low-THC weed has been freely available on the market in Switzerland since 2011, and business has since boomed, with some 130 retailers registered with customs authorities in 2017.
This taxing of legal weed could benefit federal coffers to the tune of CHF30 million a year.
More
More
How legal cannabis is changing Switzerland
This content was published on
What effect is CBD having on the Swiss economy and the legal system?
Swiss invention: 90-year anniversary of first T-bar ski lift
This content was published on
On Monday it will be 90 years since the world’s first T-bar ski lift went into service in Davos. This Swiss invention was an instant success.
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
No cannabis for scientific studies, says parliament
This content was published on
The Swiss parliament has rejected a motion to allow the use of cannabis in scientific studies investigating the drug’s effects.
‘In three years, medical cannabis could be sold in Swiss pharmacies’
This content was published on
Tens of thousands of patients in Switzerland regularly use cannabis to relieve pain and discomfort. Most of them do so illegally, however.
‘Swiss marijuana champion’ finds new markets with ‘cannabis light’
This content was published on
There’s decaffeinated coffee, alcohol-free beer, and now marijuana that doesn’t make you high. A producer reveals the hidden side of the market.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.